Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study - Report - MDSpire

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • By

  • Shigenori Kadowaki

  • Tomoyuki Otsuka

  • Keiko Minashi

  • Shinichi Nishina

  • Hiroshi Yabusaki

  • Chiaki Inagaki

  • Tomohiro Nishina

  • Hisateru Yasui

  • Hiroshi Matsuoka

  • Nozomu Machida

  • Masahiro Tsuda

  • Fumio Nagashima

  • Hisashi Hosaka

  • Junichi Matsubara

  • Hiroyuki Arai

  • Satoshi Ida

  • Yuya Kimijima

  • Yuko Matsuda

  • Manabu Muto

  • Kei Muro

  • June 18, 2026

  • 0 min

Share

Correction: An observational analysis of nivolumab combined with chemotherapy

Overview

Revise to strictly report the efficacy and safety data without additional implications.

Background

Gastric cancer remains a significant health burden, being the fifth most common cancer globally and a leading cause of cancer-related deaths. In Japan, it accounts for a substantial number of cancer deaths, highlighting the need for effective treatment strategies. The G-KNIGHT study evaluates nivolumab in combination with chemotherapy, aiming to provide insights into its real-world effectiveness.

Data Highlights

OutcomeValue95% CI
Overall Response Rate (ORR)65.6%59.9–70.9%
Disease Control Rate (DCR)91.6%87.9–94.5%
Complete Response2.7%-
Partial Response62.9%-
Stable Disease26.1%-

Key Findings

  • The corrected ORR for nivolumab combined with chemotherapy is 65.6%.
  • The DCR is reported at 91.6%.
  • 2.7% of patients achieved a complete response.
  • 62.9% of patients achieved a partial response.
  • Stable disease was observed in 26.1% of patients.

Clinical Implications

The findings from the G-KNIGHT study provide important data on the efficacy of nivolumab combined with chemotherapy in a real-world setting. Clinicians should consider these results when discussing treatment options with patients diagnosed with advanced gastric cancer.

Conclusion

The correction clarifies the efficacy data of nivolumab combined with chemotherapy, emphasizing its potential role in treating advanced gastric cancer in Japan.

Related Resources & Content

  1. Gastric Cancer, 2025 -- Correction: An observational analysis of nivolumab combined with chemotherapy
  2. Gastric Cancer — A Real-World Observational Analysis of Nivolumab Combined with Chemotherapy for Newly Diagnosed or Recurrent Advanced Gastric Cancer in Japan: Insights from the G-KNIGHT Study
  3. Gastric Cancer — Subanalysis of Japanese Participants in a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Nivolumab for Advanced Gastric or Gastroesophageal Junction Cancer Resistant to or Intolerant of Two Prior Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2)
  4. Gastric Cancer — Evaluation of Nivolumab's Safety and Efficacy in Japanese Patients with Unresectable Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer Following Chemotherapy: Insights from a Postmarketing Surveillance Study
  5. Gastric Cancer — Nivolumab Combined with Chemotherapy for Patients with Untreated, Unresectable, Advanced, or Recurrent HER2-Negative Gastric/Gastroesophageal Junction Cancer: Three-Year Outcomes from the ATTRACTION-4 Phase 3 Randomized Trial
  6. Japanese gastric cancer treatment guidelines 2025 (7th edition)
  7. New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management
  8. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 - ScienceDirect
  9. Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results | Gastric Cancer | Springer Nature Link
  10. Frontiers | Long-term outcomes of PD-1 inhibitors plus chemotherapy as first-line treatment for advanced HER2-negative gastric cancer: an updated systematic review and meta-analysis
  11. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study | Gastric Cancer | Springer Nature Link

Original Source(s)

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • by Shigenori Kadowaki, Tomoyuki Otsuka, Keiko Minashi, Shinichi Nishina, Hiroshi Yabusaki, Chiaki Inagaki, Tomohiro Nishina, Hisateru Yasui, Hiroshi Matsuoka, Nozomu Machida, Masahiro Tsuda, Fumio Nagashima, Hisashi Hosaka, Junichi Matsubara, Hiroyuki Arai, Satoshi Ida, Yuya Kimijima, Yuko Matsuda, Manabu Muto, Kei Muro

  • June 18, 2026

Related Content

Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside—a narrative review

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer